Intensity Therapeutics, Inc. (INTS)
Automate Your Wheel Strategy on INTS
With Tiblio's Option Bot, you can configure your own wheel strategy including INTS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol INTS
- Rev/Share 0.0006
- Book/Share 0.1678
- PB 2.4853
- Debt/Equity 0.0163
- CurrentRatio 3.5967
- ROIC -1.6396
- MktCap 19661106.0
- FreeCF/Share -0.2207
- PFCF -2.0696
- PE -1.5294
- Debt/Assets 0.0123
- DivYield 0
- ROE -3.7086
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
All You Need to Know About Intensity Therapeutics Inc. (INTS) Rating Upgrade to Buy
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Intensity Therapeutics Inc. (INTS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
Intensity Therapeutics, Inc. (INTS) Discusses eBioMedicine Paper Study Results and Underlying Technology Transcript
Published: October 31, 2025 by: Seeking Alpha
Sentiment: Neutral
Intensity Therapeutics, Inc. ( INTS ) Discusses eBioMedicine Paper Study Results and Underlying Technology October 31, 2025 9:00 AM EDT Company Participants Lewis Bender - Founder, President, CEO & Chairman of the Board Conference Call Participants Jacob Stephen Thomas Anthony El-Khoueiry Kumaraguru Raja - Brookline Capital Markets, LLC, Research Division Presentation Operator Welcome to the Intensity Therapeutics Discovery Lancet Discovery Group eBioMedicine Publication Webinar. [Operator Instructions] Please also note today's event is being recorded.
Read More
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France
Published: May 06, 2025 by: PRNewsWire
Sentiment: Neutral
INVINCIBLE-4 (SAKK/66/22) Study continues to recruit patients in eight sites in Switzerland SHELTON, Conn. and BERN, Switzerland , May 6, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, and The Swiss Group for Clinical Cancer Research SAKK ("SAKK"), a decentralized academic research institute that has been conducting clinical trials of cancer treatments in all major Swiss hospitals since 1965, announced that the European Medicines Agency ("EMA") has …
Read More
About Intensity Therapeutics, Inc. (INTS)
- IPO Date 2023-06-30
- Website https://www.intensitytherapeutics.com
- Industry Biotechnology
- CEO Lewis H. Bender
- Employees 5